Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
TSMC: Revenue in June was NT$442.68 billion, a year-on-year increase of 67.9%

TSMC: Revenue in June was NT$442.68 billion, a year-on-year increase of 67.9%

BlockBeatsBlockBeats2026/07/13 05:35

BlockBeats News, July 13th, TSMC stated that its revenue in June was NT$ 442.68 billion, a year-on-year increase of 67.9% and a month-on-month increase of 6.2% (May revenue was NT$ 416.98 billion).


Click on the original article link below to join the Dingcha Beating · Feishu AI News Channel, monitoring global AI hot topics and news 24/7.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.

智通财经2026/09/14 01:06
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas